Related Experiment Video
Updated: Mar 19, 2026

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
Targeting BET bromodomain proteins in solid tumors
Vaibhav Sahai1, Amanda J Redig2, Katharine A Collier3
1Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA.
Abstract:
There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal) proteins because of the association between this family of proteins and cancer progression. BET inhibitors were initially shown to have efficacy in hematologic malignancies; however, a number of studies have now shown that BET inhibitors can also block progression of non-hematologic malignancies. In this Review, we summarize the efficacy of BET inhibitors in select solid tumors; evaluate the role of BET proteins in mediating resistance to current targeted therapies; and consider potential toxicities of BET inhibitors. We also evaluate recently characterized mechanisms of resistance to BET inhibitors; summarize ongoing clinical trials with these inhibitors; and discuss potential future roles of BET inhibitors in patients with solid tumors.
Insights
Bromodomain and extra-terminal (BET) inhibitors show promise in treating various cancers, including solid tumors. This review covers their efficacy, resistance mechanisms, and future potential in oncology.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Increasing interest in bromodomain and extra-terminal (BET) protein inhibitors due to their link to cancer progression.
- Initial efficacy demonstrated in hematologic malignancies, with emerging evidence in solid tumors.
- BET proteins play a critical role in cancer cell proliferation and survival.
Approach:
- Reviewing the efficacy of BET inhibitors in various solid tumors.
- Evaluating the role of BET proteins in acquired resistance to targeted therapies.
- Assessing potential toxicities and resistance mechanisms associated with BET inhibitors.
Key Points:
- BET inhibitors demonstrate efficacy beyond hematologic cancers, showing potential in solid tumors.
- Understanding BET protein function is crucial for overcoming resistance to current cancer treatments.
- Ongoing clinical trials are exploring novel strategies and combinations involving BET inhibitors.
Conclusions:
- BET inhibitors represent a promising therapeutic strategy for a range of solid tumors.
- Further research into resistance mechanisms and toxicity profiles is essential for optimizing clinical use.
- Future applications of BET inhibitors may expand to include combination therapies and personalized treatment approaches.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Abnormal Proliferation
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

